EC Healthcare (HK:2138) has released an update.
EC Healthcare reported a mixed sales performance for the six months ending September 2024, with an overall sales volume decrease of up to 4% year-on-year, impacted by a significant 49% drop in aesthetic medical and wellness services in Mainland China. However, the company saw a promising 12% increase in sales volume from other services, highlighting diverse growth opportunities amidst a challenging market environment.
For further insights into HK:2138 stock, check out TipRanks’ Stock Analysis page.